March 16 (Reuters) - Structure Therapeutics' oral obesity drug aleniglipron delivered up to 16.3% weight loss when compared with a placebo after 44 weeks of treatment in a mid‑stage study, it said on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results